| Information | |
|---|---|
| Name of lifestyle | Antidiabetic drug |
| Third Class | Antidiabetic |
| Second Class | Drug |
| First Class | Clinical characteristics |
| Unit | NA |
| Stratification |
28084175:NA |
| Type of influence factor |
Protective factor Risk factor No statistical significance factor |
| Classification of Lifestyles |
Clinical characteristics |
| The affected types of PCa |
Total PCa Gleason 7-10 PCa Metastatic PCa |
| Number of studies involved | 1 |
| 1 Items, 1 Pages <<Prev 1 Next>> All | |||||||
|---|---|---|---|---|---|---|---|
| Research involved | |||||||
| PMID | First auther | Year | Area | Duration | Study type | Sample size | More |
| 28084175 | Antti Haringa | 2016 | Finland | 1996, 1999 | Study cohort | 78615 | baseline outcome |